Exicure Inc

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ever-Glory International Group

Shares of Ever-Glory International Group Inc. rocketed 99.1% in active trading early Monday, enough to pace all of the gainers in the premarket session, after the China-based apparel retailer and supply chain solution provider announced a share repurchase program of up to $5 million. Trading volume of 10.9 million shares, which compares with the full-day average of about 755,000 shares, made the stock the second-most active in the premarket.

Ever-Glory stock rockets to pace premarket gainers, Exicure leads most-actives list

Ipsen SA (OTC: IPSEY) and Exicure Inc (NASDAQ: XCUR) have collaborated to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington's disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation.

Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders

The stock price of Exicure Inc (NASDAQ: XCUR) increased by over 55% pre-market. This is why it happened.

XCUR Stock Increases Over 55% Pre-Market: Why It Happened

PARIS & CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington's disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day

Exicure Announces Upcoming Neuroscience Pipeline Update at Virtual R&D Day

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure's CEO will present a company update as well as participate in a series of 1x1 meetings at the Ladenburg Thalmann 2021 Healthcare Conference.

Exicure, Inc. to Present at Ladenburg Thalmann 2021 Healthcare Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced participation in upcoming conferences.

Exicure, Inc. Announces Participation in Upcoming Conferences

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer

Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO)

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc.® today reported financial results for the quarter ended March 31, 2021 and provided an update on corporate progress.

Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress

Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Exicure, Inc. (XCUR) Reports Q4 Loss, Misses Revenue Estimates

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spherical Nucleic Acid technology shows promising results in phase 0 trial in patients with glioblastoma at Northwestern University.

Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients With Glioblastoma at Northwestern University

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure reported fourth quarter and full year financial results for the year ended December 31, 2020 and provided an update on corporate progress.

Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.

Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. FDA has granted Exicure Orphan Drug Designation for its clinical product candidate, cavrotolimod.

Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exicure, Inc. (XCUR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.

Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced participation in 10th Annual SVB Leerink Global Healthcare Conference.

Exicure Announces Participation in 10th Annual SVB Leerink Global Healthcare Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure CEO, David Giljohann, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021.

Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that the U.S. FDA has granted Fast Track designations for cavrotolimod (AST-008) for two development programs.

Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of James Sulat to its Board of Directors.

Exicure Announces Appointment of James Sulat to Board of Directors

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.

Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that it will host a virtual R&D Day on January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that the U.S. Patent and Trademark Office has issued two new patents and allowed U.S. patent application 14/907,430.

Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. will participate in the 2020 Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day and the Virtual Fall Investor Summit.

News for Exicure Inc Stock (XCUR)